Primary Immune Thrombocytopenia (ITP)
Conditions
Keywords
Primary Immune Thrombocytopenia (ITP), thrombopoietin receptor agonist, PN20
Brief summary
The main aim of this clinical trial is to assess the safety and tolerability of PN20 in adult patients with primary immune thrombocytopenia (ITP). The main questions it aims to answer are: * Is PN20 safe in these patients? * Could these patients potentially benefit from PN20 treatment? Participants will * Receive one subcutaneous injection of PN20 according to weight; * Visit the clinic for assessment.
Detailed description
This is a multicenter, open-label, single-arm, dose-escalation Phase1b study aimed at evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary efficacy of a single dose of PN20 in adult patients with primary immune thrombocytopenia (ITP). The trial is a dose escalation study, including Screening (no more than 14 days), Treatment (single dose) and the post-treatment follow-up (4 weeks). And the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy of PN20 in ITP will be assessed in this study.
Interventions
DRUGPN20 treatment
Three dose cohorts, single dose, subcutaneous injections
Sponsors
Chongqing Peg-Bio Biopharm Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: 1. Aged between 18 and 65 years (inclusive), male or female; 2. Diagnosed with primary immune thrombocytopenia (ITP) and have a disease course of more than 6 months; 3. Patients who have no response or relapsed after splenectomy. Or patients who have not been splenectomised and have completed at least 1 prior treatment for ITP (such as glucocorticoids, immunoglobulin) and have failed to respond or relapsed after treatment; 4. During screening period, the mean of two platelet counts must be \< 30 × 10\^9/L, with none \>35 × 10\^9/L; 5. Fully understand and are able to comply with the requirements of the protocol, voluntarily participate and sign the informed consent form. Key
Exclusion criteria
1. History of bone marrow stem cell disorder. Any abnormal bone marrow findings other than typical of ITP. 2. Any active malignancy. If prior history of cancer other than basal cell carcinoma or cervical carcinoma in situ, no treatment or active disease within 5 years prior to signing the ICF. 3. Diagnosed with arterial thrombotic disease (such as cerebral thrombosis, transient ischemic attack, myocardial infarction, peripheral arterial disease, etc.); Patients with a history or complications of venous thrombosis (such as deep vein thrombosis, pulmonary embolism); or patients who are using anticoagulants or antiplatelet drugs at the beginning of screening. 4. Subjects who have used romiplostim or its analogs in the past and have not responded. 5. Subjects who have used eltrombopag, haitubopag, avatubopag, recombinant human thrombopoietin (rhTPO), or other drugs with c-MPl stimulating effects within the 4 weeks prior to signing the ICF. 6. Received any anti-malignancy agents (e.g., cyclophosphamide, mercaptopurine, vincristine, vinblastine, interferon-alfa) within 8 weeks prior to signing the ICF. 7. Less than 4 weeks since end of any clinical trials about therapeutic drug or device prior to signing the ICF. 8. Laboratory abnormalities with clinical significance at screening visit. 9. In the opinions of investigators, the patients are not suitable for participation in this trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse Event (AE) | Treatment and post-treatment follow-up period (28 days after a single dose) | The incidence of adverse events related to PN20. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The percentage of subjects who reach the target therapeutic platelet level after administration | Treatment and post-treatment follow-up period (28 days after a single dose) | It is defined as the proportion of subjects whose platelet count reaches at least 2 times the baseline platelet count within 28 days after administration and is within the range of 50×10\^9/L to 450×10\^9/L (inclusive). |
Countries
China
Contacts
CONTACTJing Sun
PRINCIPAL_INVESTIGATORLei Zhang
Chinese Academy of Medical Sciences
Outcome results
None listed